|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q4 FY2012
As of Dec 31, 2012
|
Q4 FY2011
As of Dec 31, 2011
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||
| Current | |||||||||||||||
| Cash | |||||||||||||||
| Prepaids and advances | |||||||||||||||
| Advances receivable | |||||||||||||||
| Total current assets | |||||||||||||||
| Total assets | |||||||||||||||
| LIABILITIES | |||||||||||||||
| Current | |||||||||||||||
| Accounts payable | |||||||||||||||
| Accrued liabilities | |||||||||||||||
| Due to related parties | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Loan | |||||||||||||||
| Total liabilities | |||||||||||||||
| SHAREHOLDERS' DEFICIENCY | |||||||||||||||
| Authorized 500,000,000 Common Shares, $0.0008 per share par value Issued and outstanding 38,906,742 Common Shares (December 31, 2024 - 38,906,742) | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Deficit accumulated during the exploration stage | |||||||||||||||
| Total shareholders' deficiency | |||||||||||||||
| Total liabilities and shareholders' deficiency | |||||||||||||||
Loading...